Beijing Sungen Biomedical Technology Co., Ltd

This early-stage study tested a new medicine called SGC001 in 38 people having a heart attack procedure. The goal was to see if it is safe and could reduce heart muscle damage and inflammation. Participants received either the drug or a placebo by IV once. The drug is not yet app…

This early-stage study tested a new drug called SGC001 in 49 healthy adults to see if it is safe and how the body processes it. The drug is being developed for future use in people who have had a heart attack. No treatment was given—this study only gathered safety information.